

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2005

DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-16133
(Commission File Number)

06-1245881
(IRS Employer Identification No.)

1100 Summer Street, Stamford, Connecticut 06905
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (203) 323-8668

N/A
(Former name or former address, if changes since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

2

Section 8 - Other Events

Item 8.01 Other Events.

On January 31, 2005, Delcath Systems, Inc. (the "Company") issued a press release relating to certain preliminary findings by National Cancer Institute researchers using the Company's technology. The Company's press release dated January 31, 2005 is incorporated herein by reference and filed as an exhibit hereto.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(a) Not applicable

(b) Not applicable.

(c) Exhibits:

Exhibit

Description

99 Press Release dated January 31, 2005 of Delcath Systems, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

By: /s/ M. S. KOLY

M. S. Koly
President and Chief Executive Officer

Date: January 31, 2005

EXHIBIT INDEX

Exhibit	Description
99	Press Release dated January 31, 2005 of Delcath Systems, Inc.

Release Date: IMMEDIATE

Contact:

M.S. Koly
Chief Executive Officer
Delcath Systems, Inc.
203/323-8668
www.delcath.com

Thomas Redington
Redington, Inc.
203/222-7399
212/926-1733
www.redingtoninc.com

National Cancer Institute Reports Encouraging
Results With Delcath Cancer Therapy

Survival Data Reported For First Time

HOLLYWOOD, FL JAN. 31 -Delcath Systems, Inc. (Nasdaq: DCTH) said National Cancer Institute researchers, using Delcath technology, achieved encouraging survival and tumor response results in a group of patients with terminal metastatic melanoma in the liver.

The findings, which are preliminary and include the largest subset of patients enrolled in the Phase I trial, were reported at the 2005 Gastrointestinal Cancers Symposium held here January 27-29 by NCI investigator Jeffrey Farma, MD, a colleague of the study's principal investigator, H. Richard Alexander, MD, head of the NCI's Surgical Metabolism Section.

The expected average survival time for patients diagnosed with inoperable cancer in the liver is six to nine months, based on historical data.

The NCI reported that patients in the Delcath study lived 50 to 120 percent longer than expected, with an overall median survival of 13 months, based on the Kaplan-Meier curve, a widely accepted method of actuarial analysis. Five of the 15 evaluable patients have lived longer than 15 months and one remained alive past 20 months. After lengthier follow-up of patients who are still alive, the survival data is expected to improve.

The NCI reported that two-thirds of the 15 patients experienced positive anti-tumor activity ranging from stabilization to a complete response. Of those, 50 percent experienced either a complete response or a partial response, which is defined as tumor mass reduction of 50 percent or more. The results were confirmed by radiographic measurement, which is considered a stringent criterion.

The study was conducted to find the optimal dose of the cancer drug melphalan using Delcath's patented drug delivery technology. Researchers also assessed how liver tumors originating from different types of cancers respond to the experimental therapy. The findings in this report suggest that melanoma is one of the tumor types that respond to Delcath therapy.

The Delcath system delivers chemotherapy directly to the liver via the hepatic artery at much higher doses than is possible with traditional intravenous therapy. As blood exits the liver, special Delcath filters trap the

-more-

chemotherapy, protecting the rest of the body from excessive toxicity. The procedure is repeatable and less invasive than traditional ways of performing isolated perfusion to effect high-dose therapy of specific body organs or regions.

Dr. Alexander's research team at the NCI has since started Phase II clinical studies to provide further data to support the safety and efficacy claims that will form the basis of eventual applications for approval to the FDA.

"We're very encouraged by the NCI's most recent findings and we are especially gratified to learn that our technology has a meaningful effect on extending survival of patients whose treatment options are very limited," said Delcath chief executive officer M. S. Koly.

The three-day, multidisciplinary symposium at which the Delcath data was presented is co-sponsored by the American Society of Clinical Oncology, the American Gastroenterological Association, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology. This is the second consecutive year the meeting was held and also marks the second year a presentation was given on the use of the Delcath system.

Delcath is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. Six U.S. and three foreign issued patents cover its technology. The company is headquartered in Stamford, CT.

#

This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.